Earnings

Usana Health Sciences Lowers FY2026 Adj EPS Guidance from $0.76 to $0.55 vs $0.76 Est; Lowers FY2026 Sales Guidance from $910.000M to $900.000M vs $908.995M Est

Nov 3, 2026 · 04:22 PM ET· updated 2h ago

Usana Health Sciences (NYSE:USNA) lowers FY2026 Adj EPS guidance from $0.76 to $0.55 vs $0.76 analyst estimate. Lowers FY2026 sales outlook from $910.000 million to $900.000 million vs $908.995 million estimate.

Why It Matters

Usana said it will make less money and sell less stuff than people expected. When a company lowers its own forecast, it means things got harder than before.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

USNA13.34

-1.38 (-9.38%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.